Abstract. The present study was undertaken in order to establish the significance of glucagon in glucose intolerance in liver cirrhosis. The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng·kg−1·min−1) or saline (154 mmol/l); somatostatin (SRIH) (500 μg/h); and SRIH plus glucagon (3 ng·kg−1·min−1). Glucagon infusion did not impair glucose tolerance, neither in normal subjects nor in patients with cirrhosis. On the other hand, in both groups glucose tolerance was impaired by SRIH infusion, presumably owing to an absolute insulin deficiency. Both in normal subjects and in cirrhotic patients, SRIH plus glucagon infusion further impaired glucose tolerance, presumably as a result of excess glucagon and concomitant insulin deficiency. In conclusion, our data show that hyperglucagonemia is not an important factor in the development of the glucose intolerance in patients with hepatic cirrhosis.
A. V. Greco, L. Altomonte, G. Ghirlanda, L. M. D'Anna, R. Manna, S. Caputo and L. Uccioli
F. Laczi, J. M. Van Ree, Lujza Balogh, Anna Szász, T. Járdánházy, A. Wágner, L. Gáspár, Zsuzsa Valkusz, Ilona Dobranovics, J Szilárd, F. A. László and D. De Wied
Abstract. The effect of desglycinamide9-[Arg8]-vasopressin (DGAVP) on memory processes was studied in patients with Korsakoff's syndrome. Intranasal treatment with DGAVP for 7 days affected neither attention nor short- and long-term memories. It is suggested that treatment with DGAVP is not indicated for all types of memory disorders, and that the beneficial effect of this treatment may depend on the integrity of certain brain structures.